- Product Description Description
- Table of Contents TOC
- List of Table & Figure LOT
- Get Free Sample PDF Sample PDF
Market Size, 2025
$312.06 MnMarket Estimate, 2026
$398.19 MnMarket Forecast, 2034
$2,798.31 MnCAGR, 2026–2034
27.60%Executive Summary: Latin America Liquid Biopsy Market
- Market Scope: Regional analysis of Latin America's liquid biopsy sector, detailing cancer types (lung, pancreatic, leukemia, other visceral cancers), diagnostic approaches (CTC, ctDNA, RNA in exosomes, extracellular vesicles), end-user laboratories, and country-level health profiles.
- Market Valuation: Valued at USD 312.06 million in 2025, reaching USD 398.19 million in 2026, and projected to expand to USD 2,798.31 million by 2034, growing at a robust CAGR of 27.60% from 2026 to 2034.
- Primary Growth Drivers: Rising prevalence of various cancers, growing focus on advanced non-invasive diagnostic tools, increasing public and private healthcare investments, and rising awareness of precision medicine.
Key Market Segment Metrics
| Category | Leading Segment (Base Position) | Fastest-Growing / High-Growth Segment |
|---|---|---|
| By Cancer Type | Lung Cancer (dominated in 2025, driven by high incidence rates and standard clinical utilization of genetic profiling) | Pancreatic Cancer & Other Visceral Cancers (anticipated at a high CAGR, fueled by urgent need for early non-invasive detection tools) |
| By Diagnostic Approach | Circulating Tumour DNA (ctDNA) (held the dominant share in 2025, anchored by high sensitivity in real-time tumor monitoring) | RNA in Exosomes & Extra-Cellular Vesicles (expected to register an accelerated CAGR, driven by multi-omic biomarker discoveries) |
| By End-Users | Reference Laboratories (captured the major market share in 2025, supported by centralized high-throughput molecular testing capabilities) | Hospital / Physician Laboratories (projected at an elevated CAGR, propelled by decentralized point-of-care oncology workflows) |
| By Country | Brazil (market leader with the largest regional share, backed by high cancer prevalence, a growing aging population, and government support) | Mexico (fastest-growing regional hub driven by rising cancer patient volumes, lifestyle risk factors, and expanding diagnostic infrastructure) |
Major Market Players & Industry Landscape
Market Structure: Highly specialized molecular diagnostics market featuring international biotechnology leaders and reference organizations advancing precision oncology across the region.
Key Companies: Janssen Diagnostics, Qiagen, Rarecells SAS, Silicon Biosystems, SRI International, Myriad Genetics, Natera, Personal Genome Diagnostics, Sysmex Inostics, Trovagene, Exosome Diagnostics, Exosome Sciences, and HansaBiomed OÜ.
Latin America Liquid Biopsy Market Size
The Latin American liquid biopsy market size was valued at USD 312.06 million in 2025 and is anticipated to reach USD 398.19 million in 2026 from USD 2,798.31 million by 2034, growing at a CAGR of 27.60% during the forecast period from 2026 to 2034.
The growth of the Latin American Liquid Biopsy Market is majorly driven by the increasing number of infectious diseases and increased focus on developing new technologies in the healthcare domain. Growing prominence for developing novel diagnostics tools for various cancer cases is also ascribed to bolster the market's demand. Growing investments in healthcare to develop accurate techniques by private and public organizations propel the market's growth rate. Additionally, the increasing prevalence of companion diagnostics and the rising demand to develop innovative technologies in favor of the end-users are anticipated to fuel the market's demand. Favorable reimbursement policies and increasing awareness over precision medicine utilization are further flourishing the growth rate of the liquid biopsy market in Latin America.
Secondarily, the rising prevalence of cancer, preference for invasive procedures, and funding in research and development for advancement in the liquid biopsy are anticipated to increase market demand. These are some of the factors driving the growth of this market in Brazil. Furthermore, liquid biopsy can detect cancer early, which helps the doctors provide proper treatment procedures, which is lucratively prompting market growth in Mexico.
Stringent government policies and transportation restrictions due to lockdown are causing downturn growth of the liquid biopsy market. COVID-19 outbreak is emphasizing the companies to develop new techniques. Novel coronavirus can have long-term effects on trade practices even after the liquid biopsy market lockdown period.
However, factors like the dearth of skilled persons and lack of proper knowledge in rural areas hinder the market's growth rate. In addition, the high cost of installing and maintaining the devices in clinical laboratories is slowly impeding the demand of the liquid biopsy market. Growing complications in the real-time monitoring procedures are slowly hampering the demand of the market in Latin America. Besides, people in rural areas are less aware of the treatment procedures available, which is gradually limiting the market's growth rate.
Geographically, the Brazilian market is the largest contributor to the Latin American liquid biopsy market. In Brazil, factors like the rising prevalence of different types of cancer and quick diagnostic technology requirements enable market growth. The growing geriatric population has elevated the demand for the liquid biopsy market. Strong Government support, increased mortality rate due to cancer, and improving healthcare infrastructure drive the market's growth in this part of the world. For a country like Brazil, with a large and aging population, new technologies take time. Therefore, spreading awareness in a rural area is needed to grow the market.
In Mexico, growth in patients who have cancer is fueling the market demand. Cancer is the second leading cause of death. In addition, higher alcohol consumption leads to develop lung, colorectal, breast, and prostate cancer. These factors are accelerating the growth of the liquid biopsy market in this region.
KEY MARKET PLAYERS
A few prominent companies operating in the Latin America Liquid Biopsy Market include
- Janssen Diagnostics
- Qiagen
- Rarecells SAS
- Silicon Biosystems
- SRI International
- Myriad Genetics
- Natera
- Personal Genome Diagnostics
- Sysmex Inostics
- Trovagene
- Exosome Diagnostics
- Exosome Sciences
- HansaBiomed OÜ
MARKET SEGMENTATION
This research report on the Latin American Liquid Biopsy Market has been segmented and sub-segmented market into the following categories.
By Cancer Type
- Lung Cancer
- Pancreatic Cancer
- Leukemia
- Other Visceral Cancers
By Diagnostic Approach
- Circulating Tumour cells (CTC)
- Circulating Tumour DNA (ctDNA)
- RNA in exosomes
- Extra-Cellular Vesicles
By End-Users
- Reference Laboratories
- Hospital/Physician Laboratories
- Academic and Research Centers
- Other End Users
By Country
- Brazil
- Argentina
- Chile
- Mexico
- Rest of Latin America